Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.
第一作者:
Masatoshi,Kudo
第一单位:
Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan. m-kudo@med.kinki.ac.jp.
作者:
主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);癌, 肝细胞(Carcinoma, Hepatocellular);双盲法(Double-Blind Method);用药计划表(Drug Administration Schedule);女(雌)性(Female);人类(Humans);Kaplan-Meiers评估(Kaplan-Meier Estimate);肝肿瘤(Liver Neoplasms);男(雄)性(Male);中年人(Middle Aged);烟酰胺(Niacinamide);苯脲化合物(Phenylurea Compounds);治疗结果(Treatment Outcome);甲胎蛋白类(alpha-Fetoproteins)
DOI
10.1007/s00535-016-1247-4
PMID
27549242
发布时间
2023-12-13
- 浏览31

Journal of gastroenterology
494-503页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文